Update shared on 16 Dec 2025
Fair value Increased 0.51%Analysts have nudged their price target on Privia Health Group slightly higher to approximately $31.26 per share from about $31.11, reflecting modest improvements in projected profitability and long term earnings multiples, despite largely unchanged growth and discount rate assumptions.
What's in the News
- Raised full year 2025 GAAP revenue guidance to a range of $2,050 million to $2,100 million, up from the prior outlook of $1,800 million to $1,900 million (company guidance)
- Management signaled increased confidence in the growth trajectory for 2025, citing stronger than previously anticipated top line performance embedded in the higher revenue range (company guidance)
- The guidance revision suggests improved operating momentum heading into 2025, with investors focusing on execution against the upgraded revenue targets (company guidance)
Valuation Changes
- Fair Value Estimate has risen slightly to approximately $31.26 from about $31.11 per share, reflecting modest upward revisions to profitability assumptions.
- Discount Rate is effectively unchanged at about 6.96 percent, indicating a stable risk and cost of capital outlook.
- Revenue Growth expectations have edged down marginally to roughly 12.04 percent from about 12.04 percent, suggesting a near flat adjustment to top line trajectory.
- Net Profit Margin has increased slightly to around 2.84 percent from approximately 2.84 percent, pointing to a very small improvement in projected profitability.
- Future P/E multiple has risen slightly to about 60.88 times from roughly 60.57 times, signaling a modestly higher valuation on forward earnings.
Have other thoughts on Privia Health Group?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.